Topiramate Solution
Product Images NDC 67877-833

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 67877-833). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Topi-fig-1 (Topi Fig 1)

This is a comparison between two groups receiving different doses of Topiramate - 50 mg/day and 400 mg/day. The study illustrates the cumulative rates for time to the first seizure over a period of 500 days. The data shows significant differences between the two groups (p=0.0002).*

FDA Label Image

Topi-fig-2 (Topi Fig 2)

This is an evaluation comparing the effects of different doses of Topiramate and a placebo on a group of participants. The study includes various dosages of Topiramate: 50 mg/day, 100 mg/day, and 200 mg/day compared to a placebo group. The data seems to include the number of participants in each group and some statistical results denoted by symbols such as "p<0.010" and "p<0.001" indicating significance levels. The study likely analyzes the rate of change from baseline to the double-blind phase in response to the different treatments.*

FDA Label Image

Topiramate 240 mL Carton Label (Topi Fig 4)

FDA Label Image

Topi-stru (Topi Stru)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.